Abstract Cervical cancer (CC) is the second most common cancer worldwide, with a well known origin, infection by high-risk human papilloma virus. Although screening programmes have led to a relevant reduction in the incidence and mortality due to CC in developed countries, it is still an important cause of mortality in young women in undeveloped countries. Clinical stage is the most relevant prognostic factor in CC and the standard of care is still based on it. In early stages, the primary treatment is surgery or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stage. In the setting of recurrent or metastatic CC the treatment is largely palliative, so it is important to develop new therapeutic strategies.
Introduction
Cervical cancer (CC) is the second most common cancer worldwide, resulting in approximately 275,000 deaths yearly. In many developing countries CC is the leading cause of cancer-related death. CC affects individuals at a younger age than other cancers do; almost 50% of cases are detected before the age of 35. Although well organised programs for Papanicolaou (Pap) screening have led to a significant decline in mortality from CC in developed countries, such programmes are costly and have not been effectively implemented in most developing countries. Persistent infection with high-risk (oncogenic) human papillomavirus (HPV) genotypes is the main cause of cervical carcinogenesis. The association between HPV and cervical is unique; no other major human cancer has a single necessary cause. HPVs cause virtually all CC, with HPV types 16 (HPV-16) and 18 (HPV-18) responsible for approximately 70%.
Cigarette smoking, early age of first sexual intercourse and several sexual partners are other risk factors related to CC [1] .
Diagnosis and staging
The most common symptoms are postcoital bleeding, vaginal discharge or intermittent spotting. These symptoms should lead physicians to perform a gynaecological inspection, cervical cytology, Pap smears and/or cervical biopsies. These procedures usually result in an accurate diagnosis. Cone biopsy is recommended if the cervical biopsy is inadequate to define invasiveness or if accurate assessment of microinvasive disease is required.
CC is clinically staged. Clinical examination represents the basis for Federation International Gynaecology and Obstetrics (FIGO) classification, which is the most widely used classification. It is clinically assessed and based on tumour size, vaginal and/or parametrial involvement, and bladder/rectum tumoral extension.
Although there is evidence that surgical staging may better define prognosis, the FIGO 2009 update does not incorporate surgical findings since surgical staging often cannot be used in low-resource countries.
The most significant change to the 1994 staging criteria is the modification of Stage IIA. Patients with Stage II CC whose tumours are larger than 4 cm are at increased risk for recurrent disease compared to those with small tumours, and 5-year survival is worse. Based on this in- (Table 1) .
It is important to note that neither lymphatic vascular space involment (lVSI) nor lymph node metastases modifies the FIGO classification.
Because of the variability of the availability and worldwide use of non-invasive radiographic imaging, the FIGO system limits the imaging to chest radiography, intravenous pyelography (IVP) and barium enema. Cystoscopy and proctosigmoidoscopy should be reserved for patients in whom there is clinical concern for bladder or rectal extension. Remarkably, FIGO has always maintained that staging is only intended for comparasion purposes and not as a guide for therapy. Although the use of magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET-CT) is not accepted for formalised staging purposes, MRI is considered the preferred complementary examination since it is superior to CT for tumour extension assessment. PET has a high sensitivity and specificity but is still under evaluation and is being compared with surgical nodal staging. laparoscopy and lymphadenectomy as a staging method can be perfomed satisfactorily and used routinely in selected institutions, but so far it is not a standard procedure.
Treatment

Early stages
After careful clinical evaluation and staging, the primary treatment of early-stage CC is either surgery or radiotherapy (RT). The treatment schema is stratified using the FIGO staging system.
Stage IA1
Extrafascial hysterectomy (i.e., simple) is commonly recommended for patients with clinical Stage IA1. Another option is modified radical hysterectomy with pelvic lymph node dissection if lymphovascular space invasion is present, because of its association with higher risk of pelvic lymphatic node metastases. However, if the patient is medically inoperable or if fertility is desired, patients with negative margins from cone biopsy could undergo observation.
Stage IA2
Stage IA2 tumours can be treated with radical hysterectomy or radical trachelectomy and pelvic lymph node dissection with (or without) para-aortic lymph node sampling. Para-aortic node dissection is indicated for patients with known or suspected pelvic nodal disease [2] .
Stage IB/II
Depending on their stage and disease bulk, patients with stage IB or IIA tumours can be treated with surgery, RT or concurrent chemoradiation.
The surgical option includes radical hysterectomy plus bilateral pelvic lymph node dissection with or without para-aortic lymph node sampling. Para-aortic node dissection is indicated for patients with larger tumours and suspected or known pelvic nodal disease. For patients who desire fertility preservation, radical trachelectomy and pelvic lymph node dissection with (or without) para-aortic lymph node sampling can be considered for stage IB1 tumours 2 cm or less .
It is worth mentioning that the pathologic results of a surgical procedure provide reliable information about risk factors in order to consider adjuvant treatment.
A prospective study in patients with node-negative stage IB identified risk factors for recurrence such as tumour diameter, deep cervical stromal invasion and lymphatic invasion. In the presence of two of them, adjuvant treatment with radiotherapy shoud be recommended as it has shown a statistical benefit in terms of progression-free survival (PFS) [3] . The Intergroup Trial 0107 showed that patients with early-stage disease and positive lymph nodes, positive margins and/or microscopic parametrial following radical surgery had a statistically significant benefit in overall survival (OS) from concurrent pelvic radiation plus chemotherapy (cisplatin/5-FU) as a complementary treatment compared to observation [4] .
For patients with clinical stage IB2 or IIA2 tumours who are treated with definitive radiation, concurrent cisplatin-containing chemotherapy has been shown to significantly improve patient survival. For stage IB2 or IIA2 tumours, we do not recommend adjuvant hysterectomy for patients undergoing primary chemoradiation.
Advanced stages
Stages IIB, III and IVA This category has traditionally included patients with stage IIB-IVA disease. However, currently patients with IB2 and IIA2 disease are also included in this category.
Concomitant chemoradiation represents the standard treatment (Table 2 ). This modality is superior to RT alone for local control, metastasis rate, disease-free and overall survival. A meta-analysis based on 18 trials with individual patient data was recently performed. Cisplatin-based chemotherapy was used in 85% of the patients. The most common regimen was cisplatin monotherapy 40 mg/m 2 on a weekly schedule.The results demonstrated a 6% and 8% improvement in absolute 5-year survival and disease-free survival with chemoradiotherapy respectively. In addition a decreasing relative effect of chemoradiotherapy on survival with increasing tumour stage was observed, with estimated absolute survival benefits of 10% (stage Ia to IIA), 7% (stage IIB) and 3% (stage III to IVA) at 5 years [5] .
For chemoradiation approach, the volume of RT is critical and is guided by assessment of nodal involvement in the pelvic and para-aortic nodes. Radiologic imaging studies (including PET-CT) are recommended for stage IB2 or greater disease. Surgical staging (i.e., extraperitoneal or laparoscopic lymph node dissection) is also an option for these patients, detecting microscopic nodal disease that is not discernible with radiologic imaging. For patients without nodal disease or with disease limited to the pelvis by surgical staging, treatment consists of pelvic RT with concurrent cisplatin-based chemotherapy and brachytherapy. However, for patients with positive para-aortic and pelvic lymph nodes by imaging, extraperitoneal lymph node dissection should be considered followed by extended-field RT, concurrent cisplatin-containing chemotherapy, and brachytherapy.
As a rule, the concurrent chemoradiotherapy should not take more than 7 weeks because a longer time periods result in worse tumour control and survival.
The role of adjuvant chemotherapy after concomitant chemoradiation remains unclear and should be included in further clinical investigations. Although a recent phase III study has observed a benefit for adjuvant chemotherapy with cisplatin-gemcitabine after chemoradiotherapy in terms of PFS and OS, these results should be confirmed before accepting this approach as a new standard of care [6] .
The role of neoadjuvant chemotherapy remains controversial and is currently under evaluation in a phase III trial (EORTC 55994) that includes FIGO stage IB2, IIA and IIB. Patients are randomised to neoadjuvant cisplatin-based chemotherapy followed by hysterectomy vs. the standard chemoradiotherapy.
Metastatic disease: stage IVB
For patients who present with distant metastatic disease (i.e., stage IVB), primary treatment is often cisplatin-based chemotherapy (see "Systemic therapy for recurrent disease"). Patients with a localised recurrence of CC after initial treatment should be evaluated to determine whether radiotherapy or surgery can be utilised for relapse.
For patients who experience local/regional recurrences who have not previously had RT or who experience recurrences outside of the previously treated RT field, therapy for relapse includes tumour-directed RT and platinumbased chemotherapy with (or without) brachytherapy. Patients with central pelvic recurrent disease after RT should be evaluated for pelvic exenteration (removal of the uterus and cervix, cystectomy, and resection of most of the rectum and vagina). This procedure would be abandoned in case of peritoneal carcinomatosis, node metastases and extension to pelvic wall. For patients with non-central recurrent disease, chemotherapy and/or best supportive care are options of therapy.
Metastatic disease
Patients who develop distant metastases, either at initial presentation or at relapse, are rarely curable. Cisplatin (C) has been considered the most effective agent in this setting. However, most of these patients have already received concurrent C/RT as primary treatment and may no longer be sensitive to single-agent platinum therapy. Therefore, Cbased combinations, such as cisplatin/paclitaxel (CP) and cisplatin/topotecan (CT), were studied in two phase III trials, the GOG 169 and the GOG 179 respectively [7, 8] .
The GOG 169 showed the CP combination was superior to C alone in terms of overall response rate (ORR) and PFS but did not show any difference for OS. The combination of CT in the GOG 179 showed statistically significant differences over C alone in ORR, PFS and OS. Following these results, the FDA approved CT for metastatic CC. However, because the combination of CP has greater response rates in patients previously treated with C as radiosensitiser, this combination was chosen as the standard arm for the upcoming GOG clinical trials. A recent phase III trial (GOG 204) in patients with advanced metastatic or recurrent cancer assessed 4 C-doublet regimens (CP vs. CT, cisplatin/gemcitabine and cisplatin/vinorelbine). The trial was closed early because it was apparent that none of the experimental arms were superior to CP. Although no significant differences were seen in terms of ORR, PFS and OS, the data suggested a positive trend for CP [9] .
As a replacement of GOG 204, the phase III (GOG 240) was launched in September 2009. This trial is evaluating the role of platinum vs. non-platinum chemotherapy with or without bevacizumab in both arms [10] .
Surveillance
There is no agreement on the best method for post-treatment surveillance for CC. The most recommended surveillance is as follows:
Patients should have an interval history and physical examination, with cervical/vaginal cytology every 3-6 months for 2 years, every 6 months for another 3-5 years, and then annually. It is important to emphasise good clinical evaluation and a high index of suspicion, because the detection rate of recurrent CC is low using cervical and vaginal cytology alone.
In patients at high risk for local-regional (central or para-aortic) failure, a PET-CT scan may be useful for detecting asymptomatic disease that is potentially curable. Although there is no consensus yet regarding how often a PET/CT should be performed, in this high-risk group at least once a year would be recommended. Annual chest radiographs are optional.
Vaginal dilators are recommended after pelvic RT, because patients who receive RT are prone to vaginal stenosis, which can impair sexual function. Dilator use can start 2-4 weeks after RT is completed and can be continued indefinitely.
